Despite Higher Sales, Atricure 3rd Quarter Loss Increased as Margins Decrease and Operational Costs Climb

Atricure Inc’s International sales revenues increased over 20% year on year as reported in the Company’s Quarterly Earnings analysis. Despite this the company’s losses widened slightly from $0.8M to $1.2M, due in part to the fact that international sales are made at lower margins and the product mix was tilted towards new and capital items. The summary is posted on Atricure’s website here.
Despite the gloomy bottom line, Atricure has reasons to be optimistic however, with approval of its Synergy Ablation System by the Circulatory System Devices Panel of the U.S. Food and Drug Administration (FDA). If this translates into full FDA approval it will mean AtriCure has the first surgical ablation device in the U.S. with an Atrial Fibrillation approval and the only device with an approval for the treatment of patients with persistent and long-standing persistent AF.
Source: Atricure